<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02553473</url>
  </required_header>
  <id_info>
    <org_study_id>2015-001481-25</org_study_id>
    <nct_id>NCT02553473</nct_id>
  </id_info>
  <brief_title>Six Versus Two Weeks Treatment With Doxycycline in Lyme Neuroborreliosis</brief_title>
  <official_title>Six Versus Two Weeks Treatment With Doxycycline in Lyme Neuroborreliosis; a Multicenter, Non-inferiority, Penta-blind, Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sorlandet Hospital HF</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sorlandet Hospital HF</source>
  <brief_summary>
    <textblock>
      Comparison of Doxycycline 200 mg once daily for six weeks versus Doxycycline 200 mg once&#xD;
      daily for two weeks + placebo for four weeks. Primary objective is to answer the question &quot;is&#xD;
      two weeks doxycycline treatment (currently suggested treatment) at least as effective as six&#xD;
      weeks doxycycline treatment in Lyme Neuroborreliosis?&quot;.Key secondary objectives are to&#xD;
      provide a better understanding of the pathogenesis and long-term complaints, and to search&#xD;
      for new biomarkers in Lyme Neuroborreliosis (LNB) by collecting clinical data, blood, and&#xD;
      cerebrospinal fluid (CSF) in a biobank for future research&#xD;
&#xD;
      Endpoints:&#xD;
&#xD;
      Primary endpoint: Improvement on a composite clinical score from inclusion to six months&#xD;
      after ended treatment defined as clinical score at inclusion minus clinical score at six&#xD;
      months.&#xD;
&#xD;
      Secondary endpoints: Improvement on a composite clinical score 12 months after ended&#xD;
      treatment. Fatigue Severity Scale (FSS),Patient Health Questionnaire (PHQ-15), Short Form 36&#xD;
      (SF-36) and blood and CSF findings at inclusion, after 6 and 12 months.&#xD;
&#xD;
      The study design is a multicenter, non-inferiority, randomized, penta-blind,&#xD;
      placebo-controlled trial. 120 patients will be included from approximately 8 Norwegian&#xD;
      hospitals.&#xD;
&#xD;
      Main inclusion criteria are neurological symptoms suggestive of LNB without other obvious&#xD;
      reasons, one or both of a) Cerebrospinal fluid pleocytosis (&gt;5 leukocytes/mm3) b) intrathecal&#xD;
      Bb antibody Production and signed informed consent. Safety assessments during the trial:&#xD;
      Comparison of clinical outcome six months after end of treatment between the two treatment&#xD;
      groups. Subjective experiences and blood tests including hematology and biochemistry for four&#xD;
      weeks after ended treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Actual">February 2021</completion_date>
  <primary_completion_date type="Actual">January 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in composite clinical score at six months after end of treatment</measure>
    <time_frame>six months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>Neuroborreliosis, Borrelia Burgdorferi</condition>
  <arm_group>
    <arm_group_label>Doxycycline for 6 weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Doxycycline 200 mg once daily for six weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Doxycycline for 2 weeks + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Doxycycline 200 mg once daily for two weeks + placebo for four weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <arm_group_label>Doxycycline for 2 weeks + placebo</arm_group_label>
    <arm_group_label>Doxycycline for 6 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Doxycycline for 2 weeks + placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Neurological symptoms suggestive of LNB without other obvious reasons and one or both&#xD;
             of&#xD;
&#xD;
               1. Cerebrospinal fluid pleocytosis ≥5 leukocytes pr mm3&#xD;
&#xD;
               2. Intrathecal Bb antibody production&#xD;
&#xD;
          2. Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age less than 18 years&#xD;
&#xD;
          -  Pregnancy, breast-feeding&#xD;
&#xD;
          -  Adverse reaction to tetracyclines&#xD;
&#xD;
          -  Treatment with cephalosporin, penicillin, or tetracycline the last 14 days&#xD;
&#xD;
          -  Serious liver or kidney disease that contraindicates use of doxycycline&#xD;
&#xD;
          -  Lactose intolerance&#xD;
&#xD;
          -  Need to use medications contraindicated according to Summary of Product&#xD;
             Characteristics of the Investigational Medicinal Product&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Marit Solheim, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sørlandet hospital HF</affiliation>
  </overall_official>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 16, 2015</study_first_submitted>
  <study_first_submitted_qc>September 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2015</study_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lyme Neuroborreliosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

